Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Genpact Limited (NYSE: G) SEC filings, including current reports, registration statements, and other disclosures filed with the U.S. Securities and Exchange Commission. Genpact describes itself as an agentic and advanced technology solutions company, and its filings offer detailed insight into how it applies process intelligence and artificial intelligence within its business, as well as how it structures its capital and governance.
Investors can review Form 8-K filings for information on material events such as quarterly financial results, leadership changes, board appointments, and financing transactions. For example, recent 8-Ks discuss third quarter 2025 financial results, appointments of directors and senior officers, and the completion of a public offering of 4.950% Senior Notes due 2030 by Genpact UK Finco plc and Genpact USA, Inc., guaranteed by Genpact and Genpact Luxembourg.
Genpact also uses shelf registration statements and prospectus supplements on Form S-3 to register securities offerings, as reflected in the documentation supporting its 2030 senior notes. Credit agreement guarantees and supplemental indentures are described in exhibits to these filings, outlining covenants, guarantees, and change-of-control provisions relevant to Genpact’s debt structure.
On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key terms in 10-K and 10-Q reports, and surface notable items from Form 4 insider transaction reports where applicable. Real-time updates from EDGAR ensure that new Genpact filings appear promptly, allowing users to monitor financial performance, capital markets activity, and corporate governance developments through the company’s official regulatory disclosures.
Insider transactions by Genpact Ltd (G): Senior Vice President and CHRO Piyush Mehta executed multiple transactions on 09/12/2025. He acquired 50,000 common shares at $31.50, and sold 50,000 shares and 26,902 shares at weighted-average prices of $42.58 (sales ranged from $42.42 to $42.73 and $42.42 to $42.70 respectively). After these transactions he beneficially owns 134,880 common shares. The filing notes he holds 10,222 shares under the ESPP (including 284 shares acquired since his prior Form 4). The Form 4 was signed by an attorney-in-fact on 09/15/2025.
Insider transactions by Genpact Ltd director and CEO Balkrishan Kalra. On 09/11/2025 Mr. Kalra sold 15,000 common shares at a weighted-average price of approximately $43.39 and sold 40,000 common shares at a weighted-average price of approximately $43.35, reducing his reported beneficial ownership to 295,246 shares. On the same date he acquired 40,000 common shares by exercising employee stock options at a $27.65 exercise price, bringing his beneficial ownership to 335,246 shares before the net sales shown. The Form 4 shows the option originally vested in two tranches (50% on 01/10/2019 and the remainder on 01/10/2021) and lists 40,000 underlying shares exercised with 2,800 derivative securities remaining reported as beneficially owned. Transactions were signed by an attorney-in-fact on 09/15/2025.
Genpact Limited reported that its Chief Accounting Officer and principal accounting officer, Donald Klunk, will separate from the company effective September 18, 2025, following a mutual agreement reached on September 11, 2025. The company states that his departure is not due to any disagreements with management or auditors regarding accounting principles, financial statement disclosures, or internal controls. Following his departure, Chief Financial Officer Michael Weiner will serve as the interim principal accounting officer until a successor is announced. Genpact also notes its appreciation for Mr. Klunk’s contributions and years of service.
Genpact Ltd. filing a Form 144 shows a proposed sale of 76,902 common shares, with an aggregate market value of $3,274,240.31, to be executed approximately on 09/12/2025 on the NYSE. The broker listed is Morgan Stanley Smith Barney LLC. The filing itemizes how the securities were acquired: 26,902 performance shares granted on 01/10/2022 and 50,000 shares from a stock option exercise on 09/12/2025 paid in cash. The filing reports nothing to report for securities sold during the past three months. The signer attests they have no undisclosed material adverse information about the issuer.
Genpact Limited (G) officer or insider filed a Form 144 to sell 55,000 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $2,384,883.50 and an approximate sale date of 09/11/2025. The filing reports 174,270,076 shares outstanding for the issuer, implying the notice covers a small fraction of outstanding stock.
The securities to be sold were acquired partly by a stock option exercise on 09/11/2025 (40,000 shares, paid in cash) and partly as performance shares granted 01/10/2022 (15,000 shares). The filer states there were no shares sold in the past three months and attests they have no undisclosed material adverse information.
Donald J. Klunk, identified as Chief Accounting Officer, reported two non-derivative transactions in Genpact Limited (G). On 09/02/2025 1,468 shares were withheld for taxes upon vesting of restricted share units at a price of $45.34, leaving 10,135 shares beneficially owned after that transaction. On 09/03/2025 he sold 2,695 shares at $44.77, leaving 7,440 shares beneficially owned following the sale. The filing notes 252 shares were acquired under the Genpact Employee Stock Purchase Plan since his prior Form 4 on March 13, 2025, and he currently holds 673 ESPP shares. The form is signed by an attorney-in-fact on 09/04/2025.
Genpact Limited (G) notice: an individual who received 2,695 restricted common shares from the issuer on 08/31/2025 intends to sell those shares on or about 09/03/2025. The filer lists Morgan Stanley Smith Barney LLC as the broker and values the shares' aggregate market value at $120,641.68 based on outstanding common shares of 174,270,076. The filing reports no other sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Genpact Limited (G) insider transaction: Sameer Dewan, Senior Vice President, reported selling 20,078 common shares on 08/28/2025 at $45 per share, leaving him with 89,148 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/29/2025. The filing shows a direct disposition of shares and does not disclose any derivative transactions or a 10b5-1 plan.
Genpact Limited (G) submitted a Form 144 notifying a proposed sale of 20,078 common shares via Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $903,510 and an approximate sale date of 08/28/2025. The filing shows the shares were acquired on 01/10/2025 from the issuer as 12,236 restricted stock and 7,842 performance shares, with payment dates listed as 01/10/2025 and no cash financing arrangements disclosed. The total outstanding common shares noted are 174,270,076, so the proposed sale represents a de minimis portion of the outstanding float. The filer certifies no undisclosed material adverse information and no sales in the past three months are reported.
Anil Nanduru, Senior Vice President at Genpact Limited (G), reported two open-market sales of company common shares on Aug 21–22, 2025. He sold 18,218 shares on 08/21/2025 at $44.50 per share and 9,744 shares on 08/22/2025 at $45.50 per share, reducing his beneficial ownership to 89,846 common shares after the transactions. The filing notes that his total holdings include 237 shares received via dividend reinvestment since his prior Form 4. The Form 4 is signed by an attorney-in-fact for the reporting person.